GlassScriptPhysician profile
Nicole Jorge
NPI 1568912368
$816.25
in general payments reported to CMS, 2019-2025
14 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.81 · 2023: $238 · 2024: $288 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.10 |
| Education | $191.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $320.71 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $94.79 | 2024-2025 | Enhertu |
| Lilly USA, LLC | $92.34 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $45.28 | 2024-2025 | Lynparza |
| Geron Corporation | $42.92 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $38.96 | 2024-2025 | Keytruda, Lynparza |
| Gilead Sciences, INC. | $33.61 | 2023 | |
| Tersera Therapeutics LLC | $31.41 | 2025 | Zoladex |
| Stemline Therapeutics INC. | $24.80 | 2024 | Orserdu |
| Novartis Pharmaceuticals Corporation | $19.94 | 2024 | |
| Paratek Pharmaceuticals, INC. | $19.27 | 2024 | Nuzyra |
| Pharmacosmos Therapeutics INC. | $18.81 | 2022 | |
| Incyte Corporation | $17.26 | 2025 | Niktimvo |
| Glaxosmithkline, LLC. | $16.15 | 2023 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Jorge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.